PTG-300 in Subjects With Hereditary Hemochromatosis
Study sponsor: Protagonist Therapeutics, Inc. · PTGX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-10-06Actual
Enrollment · participants16Actual
Source updated2025-08-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.